Bulletin
Investor Alert

Twist Bioscience Corp.

NAS: TWST

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Sep 17, 2021, 7:52 p.m.

/zigman2/quotes/207089457/composite

$

121.74

Change

0.00 0.00%

Volume

Volume 138,841

Quotes are delayed by 20 min

/zigman2/quotes/207089457/composite

Previous close

$ 113.87

$ 121.74

Change

+7.87 +6.91%

Day low

Day high

$113.24

$122.38

Open

52 week low

52 week high

$62.37

$214.07

Open

Company Description

Twist Bioscience Corp. develops proprietary semiconductor-based synthetic DNA manufacturing process. It produces synthetic biology tools such as genes, oligo pools, variant libraries, DNA data storage and NGS. The firm also produces agriculture production as well as new applications such as in vivo ...

Twist Bioscience Corp. develops proprietary semiconductor-based synthetic DNA manufacturing process. It produces synthetic biology tools such as genes, oligo pools, variant libraries, DNA data storage and NGS. The firm also produces agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. The company was founded by William Marine Banyai, Emily Marine Leproust and Bill James Peck in February 2013 and is headquartered in San Francisco, CA.

Valuation

Price to Sales Ratio

33.04

Price to Book Ratio

10.19

Enterprise Value to Sales

30.22

Total Debt to Enterprise Value

0.01

Efficiency

Revenue/Employee

171,619.00

Income Per Employee

-266,535.00

Receivables Turnover

4.68

Total Asset Turnover

0.31

Liquidity

Current Ratio

9.29

Quick Ratio

8.95

Cash Ratio

8.05

Profitability

Gross Margin

31.85

Operating Margin

-130.50

Pretax Margin

-154.88

Net Margin

-155.31

Return on Assets

-47.77

Return on Equity

-57.31

Return on Total Capital

-44.20

Return on Invested Capital

-53.92

Capital Structure

Total Debt to Total Equity

10.70

Total Debt to Total Capital

9.67

Total Debt to Total Assets

9.02

Long-Term Debt to Equity

7.80

Long-Term Debt to Total Capital

7.05

Officers and Executives

Name Age Officer Since Title
Dr. Emily Marine Leproust 47 2013 Chairman, President & Chief Executive Officer
Mr. Patrick Weiss 48 2014 Senior Vice President-Research & Development
Mr. James M. Thorburn 63 2018 Chief Financial Officer
Dr. Aaron K. Sato - - Chief Scientific Officer
Mr. Siyuan Chen - 2020 Chief Technology Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
09/13/2021 Dennis Choi
See Remarks
4,097   Award at $0 per share. 0
09/10/2021 Emily Marine Leproust
President & CEO; Director
3,480   Disposition at $120.14 per share. 418,087
09/10/2021 Emily Marine Leproust
President & CEO; Director
647   Disposition at $118.41 per share. 76,611
09/10/2021 Emily Marine Leproust
President & CEO; Director
3,462   Disposition at $117.78 per share. 407,754
09/10/2021 Emily Marine Leproust
President & CEO; Director
6,331   Disposition at $116.92 per share. 740,220
09/10/2021 Robert B. Chess
Director
4,000   Disposition at $120.23 per share. 480,920
09/10/2021 Emily Marine Leproust
President & CEO; Director
13,920   Derivative/Non-derivative trans. at $5.95 per share. 82,824
09/09/2021 Emily Marine Leproust
President & CEO; Director
15,667   Disposition at $119.04 per share. 1,864,999
09/09/2021 Emily Marine Leproust
President & CEO; Director
15,667   Derivative/Non-derivative trans. at $8.82 per share. 138,182
09/02/2021 Patrick J. Finn
Chief Commercial Officer
2,702   Disposition at $117.99 per share. 318,808
09/02/2021 Patrick J. Finn
Chief Commercial Officer
827   Derivative/Non-derivative trans. at $23.33 per share. 19,293
09/02/2021 Patrick J. Finn
Chief Commercial Officer
1,517   Derivative/Non-derivative trans. at $26.66 per share. 40,443
09/02/2021 Patrick J. Finn
Chief Commercial Officer
358   Derivative/Non-derivative trans. at $8.82 per share. 3,157
09/01/2021 Emily Marine Leproust
President & CEO; Director
419   Disposition at $116.16 per share. 48,671
09/01/2021 Emily Marine Leproust
President & CEO; Director
5,910   Disposition at $115.43 per share. 682,191
08/31/2021 Emily Marine Leproust
President & CEO; Director
906   Disposition at $110.49 per share. 100,103
08/31/2021 Emily Marine Leproust
President & CEO; Director
4,677   Disposition at $109.66 per share. 512,879
08/31/2021 Emily Marine Leproust
President & CEO; Director
24,428   Disposition at $108.92 per share. 2,660,697
08/31/2021 Emily Marine Leproust
President & CEO; Director
28,455   Derivative/Non-derivative trans. at $8.82 per share. 250,973
08/31/2021 Emily Marine Leproust
President & CEO; Director
1,556   Derivative/Non-derivative trans. at $5.95 per share. 9,258
08/30/2021 Emily Marine Leproust
President & CEO; Director
1,300   Disposition at $110.48 per share. 143,624
08/30/2021 Emily Marine Leproust
President & CEO; Director
4,530   Disposition at $109.45 per share. 495,808
08/30/2021 Emily Marine Leproust
President & CEO; Director
3,700   Disposition at $108.77 per share. 402,449
08/30/2021 Emily Marine Leproust
President & CEO; Director
2,000   Disposition at $110.08 per share. 220,160
08/30/2021 Emily Marine Leproust
President & CEO; Director
7,905   Disposition at $109.15 per share. 862,830
08/30/2021 Emily Marine Leproust
President & CEO; Director
9,654   Disposition at $108.09 per share. 1,043,500
08/30/2021 Emily Marine Leproust
President & CEO; Director
3,173   Disposition at $107.18 per share. 340,082
08/30/2021 Emily Marine Leproust
President & CEO; Director
1,400   Disposition at $105.78 per share. 148,092
08/30/2021 Emily Marine Leproust
President & CEO; Director
9,530   Derivative/Non-derivative trans. at $5.95 per share. 56,703
08/24/2021 Patrick J. Finn
Chief Commercial Officer
91   Disposition at $108.26 per share. 9,851
08/23/2021 William Marine Banyai
See Remarks; Director
1,652   Disposition at $108.09 per share. 178,564
08/23/2021 William Marine Banyai
See Remarks; Director
1,710   Disposition at $106.92 per share. 182,833
08/23/2021 William Marine Banyai
See Remarks; Director
7,151   Disposition at $106.1 per share. 758,721
08/23/2021 William Marine Banyai
See Remarks; Director
6,228   Disposition at $105.2 per share. 655,185
08/23/2021 William Marine Banyai
See Remarks; Director
1,159   Disposition at $104.24 per share. 120,814
08/23/2021 William Marine Banyai
See Remarks; Director
600   Disposition at $102.94 per share. 61,764
08/23/2021 William Marine Banyai
See Remarks; Director
1,554   Disposition at $101.72 per share. 158,072
08/20/2021 William Marine Banyai
See Remarks; Director
896   Derivative/Non-derivative trans. at $100.49 per share. 90,039
08/20/2021 Emily Marine Leproust
President & CEO; Director
2,870   Derivative/Non-derivative trans. at $100.49 per share. 288,406
08/20/2021 Patrick Weiss
Chief Operating Officer
1,228   Derivative/Non-derivative trans. at $100.49 per share. 123,401
08/20/2021 James M. Thorburn
Chief Financial Officer
1,027   Derivative/Non-derivative trans. at $100.49 per share. 103,203
08/20/2021 Patrick J. Finn
Chief Commercial Officer
1,027   Derivative/Non-derivative trans. at $100.49 per share. 103,203
08/20/2021 Paula Green
SVP of Human Resources
372   Derivative/Non-derivative trans. at $100.49 per share. 37,382
/news/latest/company/us/twst

MarketWatch News on TWST

  1. An Investor's Guide to the Promise of Synthetic Biology

    9:00 a.m. June 10, 2021

    - Barron's Online

  2. How to Invest in Tomorrow’s Big Tech Trends Today

    12:04 p.m. May 8, 2021

    - Barron's Online

  3. Twist Bioscience downgraded to underweight from neutral at J.P. Morgan

    8:21 a.m. Feb. 5, 2021

    - Tomi Kilgore

  4. Want to Use ETFs to Play Biotech? Choose Wisely.

    10:30 p.m. Jan. 15, 2021

    - Barron's Online

  5. Bullish on Tesla, Telehealth, and the Genomics Revolution

    4:35 p.m. July 15, 2021

    - Barron's Online

  6. Twist Bioscience started at market perform with $90 stock price target at SVB Leerink

    8:25 a.m. Oct. 20, 2020

    - Tomi Kilgore

  7. Twist Bioscience price target raised to $80 from $65 at JPMorgan, stock rated neutral

    7:59 a.m. Sept. 28, 2020

    - Tonya Garcia

  8. Twist Bioscience started at neutral with $27 stock price target at J.P. Morgan

    8:13 a.m. Nov. 26, 2018

    - Tomi Kilgore

/news/nonmarketwatch/company/us/twst

Other News on TWST

  1. 2 Biotech Stocks to Buy Right Now

    9:31 a.m. Today

    - Motley Fool

  2. 10-Q: TWIST BIOSCIENCE CORP

    4:13 p.m. Aug. 9, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  3. Is Cathie Wood's ARKK ETF a Buy Now?

    10:00 a.m. Aug. 6, 2021

    - Motley Fool

  4. Twist Bioscience posts Q2 topline beat, raises FY forecast

    8:34 a.m. Aug. 6, 2021

    - Seeking Alpha

  5. Twist Bioscience Q3 2021 Earnings Preview

    10:56 a.m. Aug. 5, 2021

    - Seeking Alpha

  6. Loading more headlines...

At a Glance

Twist Bioscience Corp.

681 Gateway Boulevard

San Francisco, California 94080

Phone

1 8007190671

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

09/2021

Revenue

$90.10M

Net Income

$-139.93M

2020 Sales Growth

65.7%

Employees

525.00

/news/pressrelease/company/us/twst

Press Releases on TWST

  1. Twist Bioscience to Present at Baird 2021 Global Healthcare Conference

    8:00 a.m. Sept. 8, 2021

    - BusinessWire - BZX

  2. Twist Bioscience Reports Third Quarter Fiscal 2021 Financial Results

    7:35 a.m. Aug. 6, 2021

    - BusinessWire - BZX

  3. Twist Bioscience Acquires NGS Library Preparation Maker iGenomX

    8:00 a.m. June 30, 2021

    - BusinessWire - BZX

  4. Loading more headlines...
Link to MarketWatch's Slice.